Sage Therapeutics Faces Setback After Phase 2 Trial Results
Sage Therapeutics has recently encountered a challenging moment, experiencing a notable decline in its stock price following the release of disappointing results from its Phase 2 LIGHTWAVE study. This trial focused on dalzanemdor, also referred to as SAGE-718, which is intended for treating mild cognitive impairment and mild dementia stemming from Alzheimer's disease.
Details of the LIGHTWAVE Study
The LIGHTWAVE study, which spanned 12 weeks, was designed as a randomized, double-blind, placebo-controlled trial. Its primary objective was to evaluate cognitive improvements among participants using the Wechsler Adult Intelligence Scale Fourth Edition (WAIS-IV) Coding Test. However, the results indicated that dalzanemdor did not outperform the placebo, highlighting a lack of statistically significant differences.
Trial Limitations and Findings
Regrettably, the findings showcased no substantial cognitive improvements in those treated with dalzanemdor when compared to the placebo group. Furthermore, exploratory measures such as the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and the Montreal Cognitive Assessment (MoCA) also fell short of demonstrating any meaningful benefits.
Company's Response and Future Directions
In light of these developments, Sage Therapeutics has decided to cease pursuing the clinical advancement of dalzanemdor for Alzheimer's disease. Nevertheless, the company is dedicated to continuing its research endeavors. They anticipate sharing results from the Phase 2 DIMENSION study, which centers on cognitive impairment associated with Huntington's disease, later in the year.
CEO's Statements on the Study
Barry Greene, CEO of Sage Therapeutics, expressed his disappointment regarding the LIGHTWAVE study results, stating, "While we are disappointed by the results of the LIGHTWAVE Study, we are grateful to participants, investigators, care partners, patient advocates and the Alzheimer's community who helped make this important research possible. We hope our work and these findings help to inform future research." His sentiments reflect a commitment to transparency and collaboration within the research community.
Maintaining Safety Standards
Despite the unfavorable outcomes, Sage Therapeutics emphasized that dalzanemdor was generally well-tolerated among participants, with no new safety concerns emerging from the study. This aspect remains crucial as the company navigates through the aftermath of the trial results, ensuring that patient safety remains a priority.
Frequently Asked Questions
What led to the decline in Sage Therapeutics' stock price?
The stock price dropped significantly due to disappointing topline results from the Phase 2 LIGHTWAVE study, which failed to meet its primary endpoint.
What was the primary goal of the LIGHTWAVE study?
The primary goal was to assess improvements in cognitive function in Alzheimer's patients using specific cognitive tests.
What treatments were evaluated in the LIGHTWAVE study?
The study evaluated dalzanemdor (SAGE-718) against a placebo to determine effectiveness in treating mild cognitive impairment and mild dementia.
What are the future plans for Sage Therapeutics following the trial results?
Sage Therapeutics plans to focus on ongoing research and is expecting results from the Phase 2 DIMENSION study related to Huntington's disease.
How did CEO Barry Greene respond to the study's outcome?
Barry Greene expressed disappointment but emphasized gratitude towards everyone involved in the study, reflecting hopes for future research directions.
